Answers are grounded in this paper and cite their sources.
A retrospective analysis examines treatment interruptions and responses in relapsed/refractory multiple myeloma, suggesting efficacy despite interruptions.
Elranatamab (ELRA), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, induced deep and durable responses in BCMA-naïve patients in the registrational MagnetisMM-3 (NCT04649359) study. Here, we report a post-hoc analysis in patients who experienced prolonged treatment interruption or who permanently discontinued ELRA and maintained response >6 months. MagnetisMM-3 evaluated ELRA monotherapy in patients with RRMM refractory to ≥1 IMiD, ≥1 PI, and ≥1 anti-CD38 antibody. Following step-up dosing, subcutaneous ELRA was given QW for 6 cycles then Q2W if ≥PR for ≥2 months, then Q4W after ≥6 cycles of Q2W. Primary endpoint was ORR by BICR per IMWG. Patients with treatment interruption/discontinuation >6 consecutive months and under efficacy assessment were included. Data cut-off was 10-Mar-2025. Of 187 patients enrolled in MagnetisMM-3, 28 met the analysis criteria. Included patients (46.4% female; 67.9% White) had median age 69.0 years (range, 52-84); median 5 (range, 2-14) prior treatment lines; 100% triple-class and 35.7% penta-drug refractory disease. Most common treatment-emergent adverse events (AEs) (≥10%) leading to prolonged treatment interruption/discontinuation were infections (28.6%), hematologic AEs (17.9%), fatigue (10.7%), and exacerbation of pre-existing peripheral sensory neuropathy (10.7%). Median treatment duration before interruption/discontinuation was 12.1 months (range, 1.2-35.1); median treatment-free period was 15.5 months (range, 6.5-35.4). At interruption/discontinuation, 10.7% had SD, 3.6% MR, 17.9% PR, 21.4% VGPR and 46.4% ≥CR; best overall response (any time) was PR in 7.1%, VGPR in 25.0%, and ≥CR in 67.9%. At data cutoff, median global follow-up was 39.4 months (range, 9.9-43.5); follow-up after interruption/discontinuation was 19.9 months (range, 7.3-40.6). Median PFS and OS were not reached; probability of PFS and OS at 36 months was 79.4% (95% CI, 57.0-90.9) and 84.2% (95% CI, 63.0-93.8), respectively. Six patients (21.4%) had an event (3 had PD and permanently discontinued ELRA; 3 died), 22 (78.6%) were censored. Among the 3 PD events: n=2 achieved ≥CR and had PD ≈2 and ≈3 years after the last dose; n=1 achieved PR and had PD ≈1 year after the last dose. Two patients restarted ELRA after ≈12 and ≈14 month interruptions and are continuing treatment; both maintained ≥CR as of data cut-off. Early signs of relapse resolved after treatment resumption in one patient. Most patients maintained clinical response despite prolonged treatment interruptions. These data support the feasibility of dose interruptions/treatment breaks to manage AEs without compromising ELRA’s efficacy. Studies evaluating ELRA re-initiation upon early disease progression are warranted.
No takes yet. Share an insight, caveat, or question.
Searle et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: